Recently, we initiated study of a naturally-occurring effector domain known as domain of unknown function in 5th position, or DUF5, from the MultifunctionalAutoprocessing-Repeats-in-Toxins (MARTX) toxin of Vibrio vulnificus, a bacterial pathogen associated with severe sepsis and necrotizing tissue infections. This toxic effector domain was revealed in our recent paper published in Nature Communications to represent a new class of endopeptidase that specifically processes Ras and Rap1 and thus was renamed RRSP for Ras/Rap1 specific peptidase [3] . Specifically, RRSP was found to cleave both Ras and Rap1 between D32 and Y33 within the Switch I region (residues 30-38) [3] . This region is necessary for activation of the GTPases and for their interaction with downstream protein effectors (Figure 1 ). The implications for bacterial pathogenesis is that loss of Ras and Rap1 signaling would paralyze the immune response normally activated to clear the pathogen.
However, we propose that the discovery of this protein activity will have important implications for cancer treatment. We proved that RRSP not only processes the major Ras isoforms (H, N, and K), but can also process Ras carrying G12, G13 and Q61 oncogenic mutations. In addition, RRSP can be delivered into eukaryotic cells by protective antigen (PA) when fused to the anthrax toxin LF N domain. Moreover, RRSP blocked cell division and proliferation even in colon and breast cancer cell lines carrying the Ras constitutive mutation G13D [3] .
We envision that the RRSP effector domain could be developed in the future as new anti-cancer therapeutic agent. In particular, re-engineering PA to selectively target cancer cells could be used to deliver LF N DUF5 into cells to destroy Ras signaling and thereby deregulate tumor growth and proliferation. This approach has already been validated in cell systems in which PA was fused to the epidermal growth factor for delivery of LF N -tethered cargo into cancer cells with up-regulated expression of EGFR [4] . Likewise, this system was modified with PA fused to ZHER2 affibody to bind to the HER2 receptor, a membrane protein strongly up-regulated in tumor cells, in particular breast cancer [5] . Although many LF N -tethered cargo proteins like diphtheria toxin domain A inhibit protein translation leading to cell death, RRSP would target specifically the Ras pathway, which is up-regulated in many types of human cancer.
As alternatives, RRSP effector domains could be fused or conjugated to specific antibodies to create immunotoxins able to target protein antigens up-regulated on cancer cells. Further, RRSP could be expressed and delivered by bacteria like Salmonella, which can deliver therapeutic proteins to solid tumors thereby directly killing cells, inducing apoptosis via signaling pathways, and stimulating the immune system [6] . Moreover, RRSP could be expressed by viruses engineered to specifically infect cancer cells [7] .
The ability of RRSP to cleave both normal and mutant forms of Ras indicates that any developed reagent could be successful whether used for Ras cancers, non-Ras cancers, or other Ras-associated diseases. This strategy takes advantage of billions of years of bacterial evolution to create proteins that specifically and potently disable eukaryotic cell pathways that control cell growth, survival, and motility-often the same pathways over activated in tumor cells (Figure 1 ).
